BLS Pharmaceuticals reports record FY26 revenue and earnings

BLS Pharmaceuticals Limited (ASX: BLS) has reported record audited financial results for the fiscal year ending 30 June 2026. The Australian-based company reported revenue of $74.2 million, representing a 161% increase over FY25. Net profit after tax rose to $15.4 million, up from $4.9 million in the previous year, while adjusted EBITDA reached $19.0 million.

The company’s growth was driven by international expansion in the regulated therapeutic products sector, including medicinal cannabis and psychedelic medicines. Key operational milestones included securing a two-year, $50 million supply agreement with Germany’s ADREXpharma and commencing manufacturing for Aurora Cannabis.

Additionally, BLS established a presence in Latin America through commercial supply into Costa Rica and continued development of its pharmaceutical manufacturing facility in Scotland. The company concluded the year with $13.3 million in cash reserves.